摘要
目的:探讨喜炎平注射液治疗儿童非肠道病毒71(EV71)型疱疹性咽峡炎的疗效及安全性。方法:选择115例非EV71型疱疹性咽峡炎患儿作为研究对象,按随机数字表法分为三组。A组38例患儿给予喜炎平注射液;B组40例患儿给予喜炎平注射液联合利巴韦林注射液;C组37例患儿给予利巴韦林注射液。比较各组患儿临床症状和实验室指标改善情况。结果:治疗后,A、B组患儿发热持续时间、疱疹消退时间及饮食恢复时间明显短于C组,差异均有统计学意义(P<0.05),但A、B组间的差异无统计学意义(P>0.05)。治疗第3日,A、B组患儿的C反应蛋白水平明显低于C组,差异均有统计学意义(P<0.05),但A、B组间的差异无统计学意义(P>0.05)。三组患儿在治疗期间及治疗后均未见明显不良反应。结论:非EV71型疱疹性咽峡炎有一定自限性,早期及时给予喜炎平注射液治疗,效果较好,可明显改善患者症状,且安全性较高。
OBJECTIVE：To probe into the efficacy and safety of Xiyanping injections in treatment of non EV71 herpangina in children. METHODS： 115 children with non EV71 herpangina were selected to be divided into three groups via the random number table. 38 cases in group A were given Xiyanping injections, 40 cases in group B were treated with Xiyanping combined with ribavirin injections, and 37 cases in group C received ribavirin injections. The improvement of clinical symptoms and laboratory indicators of three groups were compared. RESULTS： After treatment, the disappearance time of fever time and herpes, and recovery time of feeding in group A and B were shorter than those in control group, with statistically significant difference （ P 〈 0.05 ）, yet the difference was not statistically significant between group A and B （ P 〉 0.05 ）. The CPR level of group A and B was significantly lower than that of control group in the 3rd day after treatment, with statistically significant difference （P 〈 0.05 ）, yet the difference was not statistically significant between group A and B （ P 〉 0.05 ）. During the treatment, no serious adverse drug reactions were found during the treatment in three groups. CONCLUSIONS：Non EV71 herpangina has the self limiting. The application of Xiyanping injections at the onset of the diseases has a significant clinical efficacy, which can significantly improve patients＇ symptoms with high safety.
出处
《中国医院用药评价与分析》
2017年第3期346-348,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
